Gaines Das R E, Bristow A F
J Endocrinol. 1985 Mar;104(3):367-79. doi: 10.1677/joe.0.1040367.
Four batches of ampouled materials in ampoules coded 80/558, 81/502, 81/565 and 81/615 were evaluated by 22 laboratories in nine countries in an international collaborative study for their suitability to serve as a replacement for the First International Reference Preparation (IRP) of TSH, Human, for Immunoassay. The ampouled preparations were calibrated by immunoassay and bioassay. The preparation coded 80/558 had satisfactory stability and contained acceptably low levels of contamination with FSH and LH. Estimates of the immunoreactive TSH content of a set of specimens of serum in terms of 80/558 showed agreement in ranking order and no increase in variability compared with estimates made by assay against the First IRP. On the basis of these results, with the agreement of the participants in the study, and with the authorization of the Expert Committee on Biological Standardization of the World Health Organization, the preparation coded 80/558 was established in 1983 as the Second International Reference Preparation of TSH, Human, for Immunoassay, with a defined potency of 37 mi.u./ampoule. Preparations coded 81/502, 81/565 and 81/615 were found suitable to serve as working standards.
在一项国际协作研究中,来自9个国家的22个实验室对编码为80/558、81/502、81/565和81/615的四批安瓿装材料进行了评估,以确定它们是否适合作为人促甲状腺激素免疫测定第一国际参考制剂(IRP)的替代品。这些安瓿装制剂通过免疫测定和生物测定进行了校准。编码为80/558的制剂具有令人满意的稳定性,并且所含的促卵泡激素(FSH)和促黄体生成素(LH)污染水平可接受。根据80/558对一组血清标本中免疫反应性促甲状腺激素含量的估计,与根据第一国际参考制剂进行测定的估计相比,在排序上一致且变异性没有增加。基于这些结果,在研究参与者的同意以及世界卫生组织生物标准化专家委员会的授权下,编码为80/558的制剂于1983年被确立为人促甲状腺激素免疫测定第二国际参考制剂,规定效价为每安瓿37毫国际单位。编码为81/502、81/565和81/615的制剂被认为适合作为工作标准品。